Possibilities of Infection and Increase of Intraocular Pressure After Intravitreal Application of Bevacizumab in Treatment of Exudative Form of AMD
Jasna Muhovic-Bejtic, Emina Alimanovic-Halilovic, Suzana Pavljasevic, Darko Ler
Med Arh. 2012; 66(4): 240-242
The goal is established the frequency increase of intraocular pressure (IOP) and endophthalmitis as well as other complications that may occur after intravitreal application of bevacizumab. Subjects and methodology: The study included 45 patients and 75 eyes with exudative form of senile degeneration of macula lutea, who were treated in the General Hospital “Prim. Dr. Abdulah Nakas” from 2007. and 2010., the patients being aged between 55 and 75 years. The intraocular pres¬sure (IOP) was measured before the application of bevacizumab, and then after 1st, 2nd and 3rd dose, and it was examined by the bio-microscope two days after the application of bevacuzimab. Result: The average age of the patients treated by bevacizumab was 71.27 years (71 years, 3 months, and 7 days); 28 patients were females and 17 were males. The examination by bio-microscope indicates changes at certain number of patients. After first dose of bevacizumab, there were 9 suffu¬sions of the bulbar conjuctiva in the application area. After the second dose, there were 10 of them, while after the third dose of bevacizumab, there were 5 suffusions and 3 cases of inflammation of the anterior eye segment, anterior uveitis. As for the intraocular pressure, there is no statistically significant difference (p>0.05) for any measuring period. Conclusion: Based on the results achieved in the intravitreal application of bevacizumab in treatment of senile degeneration of macula lutea, we can conclude that there is a possibility of infection after intravitreal application of bevacizumab, but it is minimal when working in a sterile environment. Increased intraocular pressure is possible, but not necessarily to happened after the intravitreal application of the drug.
1. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal Bevacizumab vs Verteporfirin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophtalmol. 2007; 125(10):1357-1361.
2. Ehrlich R, Weinberger D, Priel E, Axer-Siegel R. Outcome of Avastin injection in patients with age-related macular degeneration and low visual acuity. Retina. 2008; 28(9): 1302-1307.
3. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal Bevacizumab for choroidal neovascularization caused by AMD (ibeNA Study): Results of a phase 1.dose-escalation study. Ophthalmol. 2006; 47(10): 4569-4578.
4. Ladas ID, Karagiannis DA, Rouvas AA, Kotsolis AI, Liotsou Vergados. Safety of repeat intravitreal injections of Bevacizumab versus Ranibizumab: our experience after 2.000 injections. Retina. 2009; 29(3): 313-318.
5. Mason JO 3rd, Frederick PA, Neimkin MG, White MF Jr, Feist RM, Thomley ML, Albert MA Jr. Incidence of haemorrhagic complications after intravitreal Bevacizumab (Avastin) or Ranibizumab (Lucentis) injections on systemically anticoagulated patients. Retina. 2010; 30(9):1386-1389.
6. Tushar RM, Walsh MK, Capone A Jr, Hassan TS, Williams G. Hyphema after intravitreal injection of Ranibizumab or Bevacizumab. Retina. 2011; 5(1): 87-90.
7. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-Lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol. 2010; 128(12):1523-1527.
8. Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010; 26(1): 105-110.
9. Maa-Yon Kim, Wan Kim Jong, Lipnja Bum Kim, Ho Min Lew. Serous retinal detachment following combined photodynamic therapy and intravitreal bevacizumab injection. Korejski J Ophthalmolol. 2009; 23(2): 124-126.
10. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injectiones of triamcinolone and bevacizumab. Eye (Lond). 2008; 22(4): 590-591.
11. Sato T, Emi K, Ikeda T, Bando H, Sato S, Morita S, Oyagi T, Sawada K. Severe intraocular inflammation following intravitreal Avastin. Ophthalmology. 2010; 117(3): 512-516.
12. Aggio FB, Farah ME, de Melo GB, d’Azevedo PA, Pignatari AC, Höfling-Lima AL. Acute endophthalmitis following intravitreal Bevacizumab (Avastin) injection. Eye (Lond). 2007; 21(3): 408-409.
13. Georgopoulos M, Polak K, Prager F, Prünte C, Schmidt-Erfurth U. Characteristics of severe intraocular inflammation following intravitreal injection of bavacizumab (Avastin). Fra J Ophthalmolol. 2009; 93(4): 457-462.
14. Moisseiev E, Goldstein M, Loewenstein A, Moisseiev J. Macular hole following intravitreal bevacizumab injection in choroidal neovascularization caused by age-related macular degeneration. Ophthalmol. 2010; 1(1): 36-41.
15. Madhusudhana KC, Newson RSB. Bevacizumab: a new hope? Editorial? Eye (Lond). 2009; 23(9): 1755-1757.
16. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal Bevacizumab (Avastin) for neovaskular age-related macular degeneration. Ophthalmology. 2006; 113(3): 363-372 e5.
17. Yang T, Jost JB. Intravitreal bevacizumab for exudative age-related macular degeneration: effect on different subfoveal membranes. Retina. 2010; 30(9): 1426-1431.
18. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA Jr, Scott IU. Intravitreal Bevacizumab for choroidal neovascularization caused by AMD (ibeNA Study): Results of a phase 1.dose-escalation study. Ophthalmol. 2006; 47(10): 4569-4578
19. Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal Bevacizumab (Avastin) injection.Eye (Lond). 2009; 23(12): 2187-2193.
20. Mason JO 3rd, White MF, Feist RM, Thomley ML, Albert MA, Persaud TO, Yunker JJ, Vail RS. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008; 28(4): 564-567.
21. Johnson D, Hollands H, Hollands S, Sharma S. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. J Ophthalmol. 2010; 45(3): 239-242.
22. Fintak DR, Shah GK, Blinder KJ, Regillo CD, Pollack J, JS Heier, Hollands H, S Sharma. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008; 28(10): 1395-1399.
23. Krebs S, Lie S, U Stolba, Zeiler F, Felke S, Binder S. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Ophthalmol. 2009; 87(6): 611-617.